Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Celltrion Inc (068270 KS)
Watchlist
721
Analysis
Health Care
•
South Korea
Celltrion Inc. produces and sells biosimilar products and also provides consignm ent processing service for other companies. The Company's main product is Abata cept which is for arthritis treatment
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Quantitative Analysis
•
23 Aug 2026 10:20
KRX Foreign Holding Weekly (Aug 21st): Samsung Electronics, SamsungElecMech, SK Hynix, SKSQUARE
We analyzed KRX foreign holding data for the past week and highlighted foreign holding changes in Samsung Electronics, SamsungElecMech, SK Hynix,...
Ke Yan, CFA, FRM
Follow
125 Views
Share
bearish
•
Thematic (Sector/Industry)
•
25 Aug 2023 03:39
Rich Men North of Richmond, Return of Mask Mandates, and New COVID Variants
In this insight, I discuss how the song Rich Men North of Richmond, return of mask mandates, and new COVID variant are all intertwined.
Douglas Kim
Follow
606 Views
Share
bullish
•
Quantitative Analysis
•
16 Aug 2026 10:20
KRX Foreign Holding Weekly (Aug 14th): SK Hynix, Samsung Electronics, SKSQUARE, Samsung Elec (PREF)
We analyzed KRX foreign holding data for the past week and highlighted foreign holding changes in SK Hynix, Samsung Electronics, SKSQUARE, Samsung...
Ke Yan, CFA, FRM
Follow
131 Views
Share
bullish
•
Quantitative Analysis
•
09 Aug 2026 10:20
KRX Foreign Holding Weekly (Aug 7th): Samsung Electronics, SamsungElecMech, Samsung Elec (PREF)
We analyzed KRX foreign holding data for the past week and highlighted foreign holding changes in Samsung Electronics, SamsungElecMech, Samsung...
Ke Yan, CFA, FRM
Follow
115 Views
Share
bullish
•
Cross Asset Strategy
•
02 Dec 2022 00:49
NPS Could Raise Investments in Korean Stocks in December 2022
At the end of September 2022, Korean stocks accounted for 13.6% of total assets of the NPS whose target for domestic stock exposure is 15.9% by end...
Douglas Kim
Follow
531 Views
Share
First
Previous
15
16
17
18
19
20
21
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.5
x